Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes
暂无分享,去创建一个
Inês Barroso | Beverley Balkau | Philippe Froguel | Christian Dina | Mark I McCarthy | Nicholas J Wareham | Claudia Langenberg | Amélie Bonnefond | Michel Marre | Ronan Roussel | Ghislain Rocheleau | Martine Vaxillaire | Sébastien Czernichow | M. McCarthy | R. Sladek | G. Rocheleau | C. Dina | S. Hadjadj | B. Balkau | G. Charpentier | P. Froguel | N. Wareham | M. Vaxillaire | I. Barroso | S. Czernichow | S. Hercberg | C. Langenberg | N. Bouatia-Naji | A. Bonnefond | O. Lantieri | M. Marre | L. Yengo | F. Payne | R. Roussel | R. Jockers | J. Guillaume | N. Clément | E. Vaillant | Nathalie Clément | Katherine Fawcett | Loïc Yengo | Emmanuel Vaillant | Jean-Luc Guillaume | Aurélie Dechaume | Felicity Payne | Serge Hercberg | Samy Hadjadj | Olivier Lantieri | Nabila Bouatia-Naji | Guillaume Charpentier | Robert Sladek | Ralf Jockers | K. Fawcett | A. Dechaume | M. McCarthy | M. McCarthy | Emmanuel Vaillant
[1] P. Galan,et al. Background and rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. SUpplementation en VItamines et Minéraux AntioXydants Study. , 1998, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.
[2] S. Dubovsky,et al. Agomelatine, a melatonin agonist with antidepressant properties , 2009, Expert Opinion on Investigational Drugs.
[3] Suzanne M. Leal,et al. A Novel Adaptive Method for the Analysis of Next-Generation Sequencing Data to Detect Complex Trait Associations with Rare Variants Due to Gene Main Effects and Interactions , 2010, PLoS genetics.
[4] Joseph S. Takahashi,et al. Disruption of the Clock Components CLOCK and BMAL 1 Leads to Hypoinsulinemia and Diabetes , 2012 .
[5] J. Todd,et al. Reduced Expression of IFIH1 Is Protective for Type 1 Diabetes , 2010, PloS one.
[6] Inês Barroso,et al. Variants in MTNR1B influence fasting glucose levels , 2009, Nature Genetics.
[7] T. Hansen,et al. MTNR1B G24E Variant Associates With BMI and Fasting Plasma Glucose in the General Population in Studies of 22,142 Europeans , 2010, Diabetes.
[8] K. Frazer,et al. Common vs. rare allele hypotheses for complex diseases. , 2009, Current opinion in genetics & development.
[9] V. Salomaa,et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia , 2010, Nature Genetics.
[10] D. Altshuler,et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion , 2009, Nature Genetics.
[11] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[12] B. Balkau,et al. [An epidemiologic survey from a network of French Health Examination Centres, (D.E.S.I.R.): epidemiologic data on the insulin resistance syndrome]. , 1996, Revue d'epidemiologie et de sante publique.
[13] C. Cooper,et al. Cohort profile: the Hertfordshire cohort study. , 2005, International journal of epidemiology.
[14] Judy H. Cho,et al. Finding the missing heritability of complex diseases , 2009, Nature.
[15] P. Fossier,et al. Monitoring of Ligand-independent Dimerization and Ligand-induced Conformational Changes of Melatonin Receptors in Living Cells by Bioluminescence Resonance Energy Transfer* 210 , 2002, The Journal of Biological Chemistry.
[16] Taylor J. Maxwell,et al. Deep resequencing reveals excess rare recent variants consistent with explosive population growth , 2010, Nature communications.
[17] S. Hadjadj,et al. Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects , 2008, Diabetes Care.
[18] M. Dubocovich,et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors , 2010, Pharmacological Reviews.
[19] Joseph S. Takahashi,et al. Circadian Integration of Metabolism and Energetics , 2010, Science.
[20] Aesha Drozdowski,et al. Standards of medical care in diabetes. , 2004, Diabetes care.
[21] E. Peschke,et al. New evidence for a role of melatonin in glucose regulation. , 2010, Best practice & research. Clinical endocrinology & metabolism.
[22] P. Elliott,et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk , 2009, Nature Genetics.
[23] C. Dina,et al. A genome-wide scan for childhood obesity-associated traits in French families shows significant linkage on chromosome 6q22.31-q23.2. , 2004, Diabetes.
[24] J. Todd,et al. Rare Variants of IFIH1, a Gene Implicated in Antiviral Responses, Protect Against Type 1 Diabetes , 2009, Science.
[25] T. Hudson,et al. A genome-wide association study identifies novel risk loci for type 2 diabetes , 2007, Nature.
[26] S. Hadjadj,et al. Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects: Results From the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEP , 2008, Diabetes Care.
[27] Ayellet V. Segrè,et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis , 2010, Nature Genetics.
[28] J. Dora,et al. Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.
[29] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[30] J. Boutin,et al. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? , 2008, British journal of pharmacology.
[31] C. Palmer,et al. Undiagnosed Glucose Intolerance in the Community: the Isle of Ely Diabetes Project , 1995, Diabetic medicine : a journal of the British Diabetic Association.
[32] P Galan,et al. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study--design, methods, and participant characteristics. SUpplementation en VItamines et Minéraux AntioXydants. , 1998, Controlled clinical trials.
[33] Thomas M Frimurer,et al. Ligand binding and micro-switches in 7TM receptor structures. , 2009, Trends in pharmacological sciences.